Cite
HARVARD Citation
Welslau, M. et al. (2014). Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer. Cancer. 120 (5), pp. 642-651. [Online].